Literature DB >> 11934825

Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity.

Miriam Andrés1, Miguel Trueba, Gilles Guillon.   

Abstract

1. The pharmacological properties of F-180, a vasopressin (VP) structural analogue, were determined on CHO cells expressing the different human vasopressin and oxytocin (OT) receptor subtypes. Binding experiments revealed that F-180 exhibited a high affinity for the human V(1a) receptor subtype (K(i)=11 nM) and was selective for this receptor subtype. 2. Functional studies performed on CHO cells expressing human V(1a) receptors indicate that similarly to AVP, F-180 can stimulate the accumulation of inositol phosphate. The activation constant (K(act)) for both F-180 and AVP was 1.7 nM. F-180 was also an agonist for the human V(2) and V(1b) receptor subtypes and an antagonist for the human OT receptor. 3. Since marked species pharmacological differences for vasopressin receptors have been described, we studied the properties of F-180 on various mammalian species. F-180 showed high affinity and good selectivity for human and bovine V(1a) receptors, but weak affinity and non selective properties for rat V(1a) receptors. 4. To assess the functional properties of F-180 on a native biological model, we performed studies on primary cultures of cells from bovine zona fasciculata (ZF). As AVP, F-180 stimulated inositol phosphate accumulation and cortisol secretion with similar efficiency. 5. In conclusion, we demonstrate that F-180 is the first selective V(1a) agonist described for human and bovine vasopressin receptors. Therefore F-180 can be used as a powerful pharmacological tool to characterize the actions of vasopressin that are mediated by V(1a) receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934825      PMCID: PMC1573299          DOI: 10.1038/sj.bjp.0704634

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.

Authors:  M Saito; A Tahara; T Sugimoto
Journal:  Biochem Pharmacol       Date:  1997-06-01       Impact factor: 5.858

2.  Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension.

Authors:  C Bernadich; J C Bandi; P Melin; J Bosch
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

3.  Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors.

Authors:  C Barbeis; M N Balestre; S Jard; E Tribollet; Y Arsenijevic; J J Dreifuss; K Bankowski; M Manning; W Y Chan; S S Schlosser
Journal:  Neuroendocrinology       Date:  1995-08       Impact factor: 4.914

4.  Comparative involvement of cyclic nucleotide phosphodiesterases and adenylyl cyclase on adrenocorticotropin-induced increase of cyclic adenosine monophosphate in rat and human glomerulosa cells.

Authors:  M Côté; M D Payet; E Rousseau; G Guillon; N Gallo-Payet
Journal:  Endocrinology       Date:  1999-08       Impact factor: 4.736

5.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Authors:  C Serradeil-Le Gal; C Lacour; G Valette; G Garcia; L Foulon; G Galindo; L Bankir; B Pouzet; G Guillon; C Barberis; D Chicot; S Jard; P Vilain; C Garcia; E Marty; D Raufaste; G Brossard; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

6.  Vasopressin receptors in human adrenal medulla and pheochromocytoma.

Authors:  E Grazzini; C Breton; S Derick; M Andres; D Raufaste; F Rickwaert; G Boccara; P Colson; N C Guérineau; C Serradeil-le Gal; G Guillon
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

7.  Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.

Authors:  N Cotte; M N Balestre; S Phalipou; M Hibert; M Manning; C Barberis; B Mouillac
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

8.  Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.

Authors:  Y Yamamura; H Ogawa; H Yamashita; T Chihara; H Miyamoto; S Nakamura; T Onogawa; T Yamashita; T Hosokawa; T Mori
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

9.  Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Authors:  C Serradeil-Le Gal; J Wagnon; C Garcia; C Lacour; P Guiraudou; B Christophe; G Villanova; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

10.  Effect of nitric oxide on rat adrenal zona fasciculata steroidogenesis.

Authors:  C B Cymeryng; L A Dada; E J Podestá
Journal:  J Endocrinol       Date:  1998-08       Impact factor: 4.286

View more
  5 in total

1.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

2.  Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns.

Authors:  Sonia Terrillon; Claude Barberis; Michel Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-02       Impact factor: 11.205

3.  Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.

Authors:  Rafik Marir; Anne Virsolvy; Kazimierz Wisniewski; Julie Mion; Dominique Haddou; Evelyne Galibert; Zahia Meraihi; Michel G Desarménien; Gilles Guillon
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 4.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

5.  Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species.

Authors:  Markus Muttenthaler; Åsa Andersson; Irina Vetter; Rohit Menon; Marta Busnelli; Lotten Ragnarsson; Christian Bergmayr; Sarah Arrowsmith; Jennifer R Deuis; Han Sheng Chiu; Nathan J Palpant; Margaret O'Brien; Terry J Smith; Susan Wray; Inga D Neumann; Christian W Gruber; Richard J Lewis; Paul F Alewood
Journal:  Sci Signal       Date:  2017-12-05       Impact factor: 8.192

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.